Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Verastem, Inc.
  6. Summary
    VSTM   US92337C1045

VERASTEM, INC.

(VSTM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
2.67(c) 2.61(c) 2.55(c) 2.59(c) 2.61 Last
778 409 1 106 907 1 462 061 971 585 733 000 Volume
-0.74% -2.25% -2.30% +1.57% +0.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,43 M - -
Net income 2021 -63,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,46x
Yield 2021 -
Sales 2022 12,5 M - -
Net income 2022 -58,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,56x
Yield 2022 -
Capitalization 472 M 472 M -
Capi. / Sales 2021 330x
Capi. / Sales 2022 37,7x
Nbr of Employees 49
Free-Float 99,3%
More Financials
Company
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The CompanyÔÇÖs marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a... 
More about the company
Ratings of Verastem, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about VERASTEM, INC.
08:16aVerastem Oncology Appoints Michelle Robertson to Board of Directors - Form 8-K
PU
08:14aVERASTEM, INC. : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
07:01aVerastem Oncology Appoints Michelle Robertson to Board of Directors
BU
09/30Verastem Oncology Reports the Appointment of Louis J. Denis as Chief Medical Officer
CI
09/24VERASTEM ONCOLOGY : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/22VERASTEM : Oncology Names Louis Denis Chief Medical Officer
MT
09/22VERASTEM ONCOLOGY : Appoints Louis J. Denis, M.D., as Chief Medical Officer
BU
09/22Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
CI
09/20Health Care Stocks Sink with Broader Markets
MT
09/20VERASTEM : Amgen to Evaluate VS-6766, Sotorasib Combo Therapy in Non-Small Cell Lung Cance..
MT
09/20Wall Street Futures Tumble as China's Evergrande Default Risk Weighs on Sentiment
MT
09/20Health Care Stocks Trade Lower Pre-Bell Monday
MT
09/20VERASTEM : Health Care
MT
09/20US Futures Fall, China's Evergrande Default Risk Weighs on Sentiment
MT
09/20VERASTEM : Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeu..
PR
More news
News in other languages on VERASTEM, INC.
09/20Les actions du secteur de la santé sombrent avec les marchés plus larges
09/20Verastem déclare que l'étude de la thérapie combinée avec le VS-6766 montre un potentie..
More news
Analyst Recommendations on VERASTEM, INC.
More recommendations
Chart VERASTEM, INC.
Duration : Period :
Verastem, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERASTEM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,61 $
Average target price 6,25 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Brian M. Stuglik Chief Executive Officer & Director
Daniel W. Paterson President & Chief Operating Officer
Robert E. Gagnon Chief Financial & Business Officer
Jonathan Pachter Chief Scientific Officer
Louis J. Denis Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VERASTEM, INC.21.60%468
GILEAD SCIENCES, INC.16.25%84 845
BIONTECH SE258.67%71 229
WUXI APPTEC CO., LTD.23.63%64 399
REGENERON PHARMACEUTICALS22.57%59 906
VERTEX PHARMACEUTICALS-22.12%47 992